{"title":"네이버 금융 ─ 뉴스 ─ 시황·전망","url":"https://finance.naver.com/news/news_list.naver?mode=LSS3D&section_id=101&section_id2=258&section_id3=401","favicon":"https://finance.naver.com/news/favicon.ico","elements":[{"title":"코스닥, 오미크론에 1%가까이 하락 출발…‘960선’","contents":"<a href=\"/news/news_read.naver?article_id=0005098428&amp;office_id=018&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=401&amp;date=20211202&amp;page=1\" title=\"코스닥, 오미크론에 1%가까이 하락 출발…‘960선’\">코스닥, 오미크론에 1%가까이 하락 출발…‘960선’</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0005098428&office_id=018&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=401&date=20211202&page=1","retrieved":1638404383755},{"title":"코스피, 오미크론 공포 지속에 하락 출발…‘2880선’","contents":"<a href=\"/news/news_read.naver?article_id=0005098425&amp;office_id=018&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=401&amp;date=20211202&amp;page=1\" title=\"코스피, 오미크론 공포 지속에 하락 출발…‘2880선’\">코스피, 오미크론 공포 지속에 하락 출발…‘2880선’</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0005098425&office_id=018&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=401&date=20211202&page=1","retrieved":1638404383757},{"title":"[특징주]브레인즈컴퍼니, IT인프라 수요 증가 기대에 '강세'","contents":"<a href=\"/news/news_read.naver?article_id=0005098417&amp;office_id=018&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=401&amp;date=20211202&amp;page=1\" title=\"[특징주]브레인즈컴퍼니, IT인프라 수요 증가 기대에 '강세'\">[특징주]브레인즈컴퍼니, IT인프라 수요 증가 기대에 '강세'</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0005098417&office_id=018&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=401&date=20211202&page=1","retrieved":1638404383759},{"title":"[특징주]국전약품, 치매치료제 임상1상 IND 승인에 급등","contents":"<a href=\"/news/news_read.naver?article_id=0005098414&amp;office_id=018&amp;mode=LSS3D&amp;type=0&amp;section_id=101&amp;section_id2=258&amp;section_id3=401&amp;date=20211202&amp;page=1\" title=\"[특징주]국전약품, 치매치료제 임상1상 IND 승인에 급등\">[특징주]국전약품, 치매치료제 임상1상 IND 승인에 급등</a>","link":"https://finance.naver.com/news/news_read.naver?article_id=0005098414&office_id=018&mode=LSS3D&type=0&section_id=101&section_id2=258&section_id3=401&date=20211202&page=1","retrieved":1638404383761}]}